Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Neoadjuvant Sonidegib for Basal Cell Carcinomas in Cosmetically Challenging Locations
NCT03534947Phase 2Completed
- Sponsor
- Melanoma Institute Australia
- Start
- Jul 2019
- Primary completion
- Mar 2025
- Modality
- Allosteric Modulators
- Countries
- 1
01
Overview
A Phase 2 trial of sonidegib in basal cell carcinoma (BCC), sponsored by Melanoma Institute Australia. Started Jul 2019; status: completed.
02
Drugs
sonidegib
03
Conditions
basal cell carcinoma (BCC)
Beyond the preview
Go deeper on NCT03534947.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03534947.